ArticleVirus research2023
A K-17 serotype specific Klebsiella phage JKP2 with biofilm reduction potential.
Article in Virus research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Antibiofilm efficacy and genomic characterization of a lytic bacteriophage targeting MDR uropathogenic Escherichia coli.Archives of microbiology · 2026Article
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Genomic insights into phage SGP007 reveal a potent therapeutic candidate for targeted control of salmonellosis in poultry.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Antimicrobial Potential and Genomic Insights of Novel Klebsiella Phage SBP against K-112 Serotype.Current microbiology · 2026Article
- Longitudinal genomic insights into resistance and virulence dynamics of Klebsiella pneumoniae clinical isolates from Pakistan.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Isolation and characterization of lytic bacteriophages with therapeutic potential against multidrug resistant Klebsiella pneumoniae from Ethiopia.Scientific reports · 2026Article
- Novel Autographivirales phages Kiwi, Nika and Pie targeting Klebsiella pneumoniae K14: Isolation, characterisation, genome analysis and study of the bacterial polysaccharide degradation.Archives of virology · 2026Article
- Genomic and functional characterization of a lyticFrontiers in microbiology · 2026Article
- Biological characterization and genome analysis of Pseudomonas phage ZAM-Pa99 as a promising anti-biofilm agent.Molecular biology reports · 2025Article
- Genomic and physiochemical characterization of two lysogenic bacteriophages, ΦCP5(17) and ΦCP17(i), infecting Clostridium perfringens.Archives of virology · 2025Article
- Phage vB_KpnM_JYSS3 encodes a novel polysaccharide depolymerase that exhibits specific activity against K2-type carbapenem-resistant Klebsiella pneumoniae.BMC microbiology · 2025Article
- PSK1, a bacteriophage with antibacterial activity against extended-spectrum-beta-lactamase-producing Escherichia coli sequence type 131 with serotype O25:H4.Archives of virology · 2025Article
- Isolation and characterization of a novel phage targeting Klebsiella pneumoniae K2 capsular type.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Analysis of a novel phage as a promising biological agent targeting multidrug resistant Klebsiella pneumoniae.AMB Express · 2025Article
- Isolation, Characterization, and Anti-Biofilm Activity of a NovelAntibiotics (Basel, Switzerland) · 2025Article
- Characterisation of four novel bacteriophages targeting carbapenem-resistantCurrent research in microbial sciences · 2025Article
- Relationship between biofilm formation and antibiotic resistance ofFrontiers in cellular and infection microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Klebsiella pneumoniae is an opportunistic pathogen responsible for nearly one-third of all Gram-negative infections. Increasing antibiotic resistance has pushed scientists to look for alternative therapeutics. Bacteriophages have emerged as one of the promising alternatives. In the current study, the Klebsiella phage JKP2 was isolated from a sewage sample and characterized against the K-17 serotype of K. pneumoniae. It produced bulls-eye-shaped clear plaques and has a latent period of 45 min with a burst size of 70 pfu/cell. It remained stable at tested pH (5 to 10) and temperatures (37 to 60 °C). Its optimum temperature for long-term storage is 4 °C and -80 °C. The JKP2 showed its infectivity against the K. pneumoniae K-17 serotype only. It controlled planktonic cells of K. pneumoniae 12 h post-incubation. At MOI-1, it efficiently eliminated 98% of 24 and 96% of 48-hour-old biofilm and 86% and 82% of mature biofilm of day 3 and 4, respectively. The JKP2 has an icosahedral capsid of 54 ± 0.5 nm with a short, non-contractile tail, measuring 12 ± 0.2 nm. It possesses a double-stranded DNA genome of 43.2 kbp with 54.1% GC content and encodes 54 proteins, including 29 with known functions and 25 with unknown functions. JKP2 was classified as Drulisvirus within the Autographiviridae family. It uses a T7-like direct terminal repeat strategy for genome packaging. JKP2 can be applied safely for therapeutic purposes as it does not encode an integrase or repressor genes, antibiotic resistance genes, bacterial virulence factors, and mycotoxins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.